GSTT2B

Across TCGA pan-cancer cohorts, GSTT2B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GSTT2B data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GSTT2B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GSTT2B expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, HNSC, and UCEC are the cancer types where GSTT2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	III,IV	0.917	0.362	.001	16	view →
HNSC	DFS	Median	All	0.537	0.826	.005	5	view →
UCEC	DFS	Median	II,III,IV	0.482	0.924	.016	4	view →
LSCC	DFS	Median	III,IV	0.930	0.630	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GSTT2B–LUAD (DFS)

Open the LUAD breakdown →